News - GlaxoSmithKline

Filter

Current filters:

GlaxoSmithKline

Popular Filters

201 to 225 of 434 results

GlaxoSmithKline initiates Ph III study to test dabrafenib and trametinib combo for BRAF positive melanoma

04-02-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) has initiated COMBI-AD, a Phase III study evaluating the combination…

BiotechnologydabrafenibGlaxoSmithKlineJapan TobaccoOncologyPharmaceuticalResearchtrametinib

GlaxoSmithKline and Biological E set up JV to develop combination vaccine

29-01-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and Indian vaccines company Biological E have entered into…

Asia-PacificBiological E LtdGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalResearchVaccines

Another stumbling block for Impax Pharma's Rytary

22-01-2013

Impax Pharmaceuticals, the branded products division of Impax Laboratories (Nasdaq: IPXL), revealed on…

GlaxoSmithKlineImpax LaboratoriesNeurologicalNorth AmericaPharmaceuticalProductionRegulationRytary

GSK and Canadian researchers claim major step toward an Alzheimer's vaccine

16-01-2013

A team of researchers from Canada's Universite Laval, CHU de Quebec, and UK pharma giant GlaxoSmithKline…

GlaxoSmithKlinemonophosphoryl lipid ANeurologicalPharmaceuticalResearchVaccines

Japan's seasonal flu vaccines market analysis

16-01-2013

The Japanese influenza vaccine market is valued at around $702 million in 2012, according to a new report…

Anti-viralsAsia-PacificGlaxoSmithKlineMarkets & MarketingPharmaceuticalSanofiVaccines

Flu vaccine innovation needed to protect children, says GlobalData health care expert

13-01-2013

The last time the USA confronted a flu season this early, the virus claimed the lives of nearly 50,000…

Anti-viralsAstraZenecaFluarixFluMistGlaxoSmithKlinePharmaceuticalResearchVaccines

GlaxoSmithKline and Theravance file for EU approval of UMEC/VI for COPD

10-01-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) yesterday submitted…

AnoroBiotechnologyEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceUMEC/VIumeclidiniumvilanterol

Amgen in $180 mill deal with BIND; Priaxon accord with GlaxoSmithKline

09-01-2013

BIND Biosciences, a US clinical stage investor backed company, and Amgen (Nasdaq: AMNG), the world's…

AmgenBIND BiosciencesBiotechnologyGlaxoSmithKlineLicensingOncologyPharmaceuticalPriaxon

News briefs on Sanofi, Novo Nordisk and GlaxoSmithKline/Amicus

20-12-2012

Two US subsidiaries of French drug major Sanofi (Euronext: SAN) have agreed to pay $109 million to resolve…

Amicus TherapeuticsAmigalDiabetesFIAspFinancialGlaxoSmithKlineHyalganIDegLiraLegalNorth AmericaNovo NordiskPharmaceuticalRare diseasesResearchSanofi

Sales of antiretroviral agents for HIV will decline slightly over next decade

18-12-2012

Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

GlaxoSmithKline gains FDA approval of four-strain seasonal influenza vaccine

17-12-2012

The US Food and Drug Administration has approved UK pharma giant GlaxoSmithKline's (LSE: GSK) Fluarix…

FluarixGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationVaccines

Mayne Pharma to acquire Kapanol in Australia from GlaxoSmithKline for up to A$14.0 million

16-12-2012

Australia's Mayne Pharma Group (ASX: MYX) has entered into a binding agreement to acquire Kapanol and…

Asia-PacificGlaxoSmithKlineKapanolMayne PharmaMergers & AcquisitionsNeurologicalPharmaceutical

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation

14-12-2012

In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

Great expectations for GlaxoSmithKline R&D newsflow

13-12-2012

Essentially, analysts at Panmure Gordon & Co anticipate a lot of pipeline newsflow from UK pharma giant…

AdvairdarapladibFinancialGlaxoSmithKlineMAGE-A3PharmaceuticalResearch

Sales of cancer pain therapies set to grow to $5.2 billion in the G7 by 2021

13-12-2012

Sales of cancer pain therapies will increase to $5.2 billion in 2021 in leading seven markets (the USA,…

AmgenBiotechnologyDaiichi SankyodenosumabGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRanmarkXgeva

201 to 225 of 434 results

Back to top